Publications by authors named "Samuel A Jacobs"

Claim this Profile
N
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.
Tanner J Freeman, Thomas J George, Samuel A Jacobs, Greg Yothers, Tatjana Kolevska

Cancer Chemother Pharmacol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2 breast cancer that limits trastuzumab deruxtecan efficacy.
Dong Hu, Xiaoshuang Lyu, Zheqi Li, Prasanna Ekambaram, Anushka Dongre, Samuel A Jacobs

Nat Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies.
Maggie Chon U Cheang, Mothaffar Rimawi, Stephen Johnston, Samuel A Jacobs, Judith Bliss

NPJ Breast Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Samuel A Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J Montero

Breast Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Samuel A Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J Montero

Breast Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma.
William A Hall, Jiahe Li, Y Nancy You, Marc J Gollub, Joseph R Grajo, Samuel A Jacobs

J Clin Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab.
Lawrence D Wagman, David A Geller, Samuel A Jacobs, Nicholas J Petrelli, Carmen J Allegra

J Surg Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Charles E Geyer, Hanna Bandos, Priya Rastogi, Samuel A Jacobs, André Robidoux

Breast Cancer Res Treat· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Charles E Geyer, Hanna Bandos, Priya Rastogi, Samuel A Jacobs, André Robidoux

Breast Cancer Res Treat· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER/HER2 Breast Cancer.
Mitch Dowsett, Lucy Kilburn, Mothaffar F Rimawi, C Kent Osborne, Katherine Pogue-Geile, Samuel A Jacobs

Clin Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
Osama E Rahma, Greg Yothers, Theodore S Hong, Marcia M Russell, Y Nancy You, Samuel A Jacobs

JAMA Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib-Plus-Cetuximab in Quadruple-WT () Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.
Samuel A Jacobs, James J Lee, Thomas J George, James L Wade, Philip J Stella

Clin Cancer Res· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
Arvind Dasari, Van K Morris, Carmen J Allegra, Chloe Atreya, Al B Benson, Samuel A Jacobs

Nat Rev Clin Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.
Mitch Dowsett, Matthew J Ellis, J Michael Dixon, Oleg Gluz, John Robertson, Samuel A Jacobs

NPJ Breast Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Samuel A Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde

Breast Cancer Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 breast cancer.
Samuel A Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde

Breast Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.
Jame Abraham, Albert J Montero, Rachel C Jankowitz, Mohamad Adham Salkeni, Jan H Beumer, Samuel A Jacobs

J Clin Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.
Thomas J George, Aaron J Franke, A Bapsi Chakravarthy, Prajnan Das, Arvind Dasari, Samuel A Jacobs

Cancer· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations.
Rekha Pal, Ning Wei, Nan Song, Shaoyu Wu, Rim S Kim, Samuel A Jacobs

PLoS One· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
Stephen Johnston, Shannon Puhalla, Duncan Wheatley, Alistair Ring, Peter Barry, Samuel A Jacobs

J Clin Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Joanne L Blum, Patrick J Flynn, Greg Yothers, Lina Asmar, Charles E Geyer, Samuel A Jacobs

J Clin Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
John W Smith, Marc E Buyse, Priya Rastogi, Charles E Geyer, Samuel A Jacobs

Clin Breast Cancer· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 activating mutations are targets for colorectal cancer treatment.
Shyam M Kavuri, Naveen Jain, Francesco Galimi, Francesca Cottino, Simonetta M Leto, Samuel A Jacobs

Cancer Discov· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.
Jame Abraham, André Robidoux, Antoinette R Tan, Steven Limentani, Keren Sturtz, Samuel A Jacobs

Breast Cancer Res Treat· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study.
Rachel C Jankowitz, Jame Abraham, Antoinette R Tan, Steven A Limentani, Marni B Tierno, Samuel A Jacobs

Cancer Chemother Pharmacol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis